| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1177/1078155207080804 Overview of targeted therapies in OncologyPharmacy Communities Oncology Network Educator, BC Cancer Agency - Centre for the Southern Interior, 399 Royal Ave, Kelowna, BC, Canada V1Y 5L3, rkalyn{at}bccancer.bc.ca Background: Recent scientific advances have provided a map of the human genome along with a better understanding of the processes that transform healthy cells into diseased cells. This has led to the emergence of a new class of drugs called targeted therapies. Objective: To describe the classifications and basic pharmacology of targeted therapies. Methods: A literature search was performed for peer reviewed journal articles using Medline (1996—2007), Embase (1996—2007) and Google. The search was performed using keywords such as angiogenesis inhibitors, cancer vaccines, gene therapy, monoclonal antibodies, small molecules, proteasome inhibitors, targeted therapy and tyrosine kinase inhibitors. Conclusions: A review of the basic pharmacology is described in this article, including the following major categories of targeted therapies: • Small molecule drugs • Monoclonal antibodies • Apoptosis-inducing drugs • Angiogenesis Inhibitors • Cancer vaccines • Gene therapy J Oncol Pharm Practice (2007) 13: 199—205.
Key Words: angiogenesis inhibitors antineoplastic agents • antisense oligonucleotides • cancer vaccines • drug therapy • epidermal growth factor inhibitors • gene theropy monoclonal antibodies • oncogenes • pharmacology • protease inhibitors • small molecules • suicide genes • targeted therapy • tumor suppressor genes • tyrokinase inhibitors • vascular endothelial growth factor inhibitors
|
 |
|
|
 |
 |
Sign In to gain access to subscriptions and/or personal tools.
